NCT03602612View on ClinicalTrials.gov

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

January 1, 2023

Study Completion Date

April 21, 2026

Conditions
Myeloma-MultipleMyeloma, Plasma-Cell
Interventions
DRUG

Cyclophosphamide

300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

DRUG

Fludarabine

30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3

BIOLOGICAL

Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells

0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH